2-苯甲酰基嘧啶类化合物的合成与生物活性

2-嘧啶氧基-N-芳基苄胺类化合物结构经过两次骨架结构优化后得到2-苯甲酰基嘧啶类化合物二次先导结构.在二次先导结构基础上,共设计并合成了36个化合物,所有化合物结构经1H NMR、13C NMR、HRMS确认,并进行了室内杀菌活性筛选,对各部位取代基进行了逐次优化.结果表明2-苯甲酰基嘧啶类化合物中R1取代基以2位卤素或烷基取代的苯环或杂环活性最好;中间苯环6位引入氟原子活性保持;嘧啶环4,6位甲氧基取代活性较好,5位甲基取代活性大大降低;羰基被还原为羟基后活性消失.其中2,3-二氯-N-[2-(4,6-二甲氧基嘧啶-2-甲酰基)苯氧基]-N-甲基苯甲酰胺(4AHl)、2,5-二氯-N-[2-(4,6-二甲氧基嘧啶-2-甲酰基)苯氧基]-N-甲基苯甲酰胺(4AHn)及N-[2-(4,6-二甲氧基嘧啶-2-甲酰基)-3-氟苯氧基]-N,2-二甲基苯甲酰胺(4AFd)对黄瓜白粉病的杀菌活性与对照样苯菌酮相当.     

N-(4-取代嘧啶-2-基)苄基磺酰脲和苯氧基磺酰脲的3D-QSAR研究

采用比较分子力场分析(CoMFA)方法,对两类单取代嘧啶类似物、6个N-(4-取代嘧啶-2-基)-2-甲氧羰基苄基磺酰脲(1a～1f)和14个N-(4-取代嘧啶-2-基)-2-取代苯氧基磺酰脲(2a～2n)进行三维定量构效关系(3D-QSAR)研究.建立了一个较为可靠的预测模型.结果表明,分子中苯环邻位、嘧啶环形成氢键的N原子处以及嘧啶环4位和6位附近负电荷增加;苯环邻位乙氧基的CH₂CH₃附近选择带正电的原子;苯环邻位乙氧基附近空间体积增加,而嘧啶环4位甲氧基稍远处取代基的立体位阻不超过此位置,将有利于提高活性.最后解释了修饰磺酰脲的除草剂仍具有较高活性的原因.     

取代嘧啶化合物的合成和生物活性研究

合成了14个新型取代嘧啶类化合物,结构经质谱、红外光谱、氢核磁共振光谱和元素分析确证.杀虫、杀菌和除草活性测定结果表明,部分化合物具有良好的杀菌活性.在嘧啶环的2-位上导入二甲氨基时表现出杀菌活性,但在嘧啶环的5-位上有甲基取代基时,杀菌活性下降.在嘧啶的4-位导入苯氧基时,显示出良好的杀菌活性,如化合物3b,3c和3e,苯环上的最优取代基是2-硝基-4-三氟甲基.     

嘧啶（硫）醚类化合物的合成及除草活性

以2,4-二氯嘧啶为起始物设计并合成了一系列4-芳(硫)氧基-2-氯嘧啶和4-芳氧基-2-二甲氨基嘧啶化合物。利用2,4-二氯嘧啶2个氯原子的活性差异,酚取代嘧啶环上4位氯原子,然后二甲氨基取代2位的氯原子。所合成的化合物均经过了1H NMR和元素分析确证。为了确证酚首先在嘧啶环的4位发生亲核取代反应,用X衍射法测定了化合物3d的单晶结构。初步生物活性测定结果表明,大部分化合物都表现出一定的除草活性,其中化合物7c、7j、7k和7m在1.0×10-4g/mL质量浓度下对油菜的抑制率达到了80%以上。     

磷酸二酯酶4b抑制剂定量构效关系及分子对接研究

磷酸二酯酶 4( PDE4)是第二信使环磷酸腺苷( cAMP)选择性高亲和力的水解酶,影响气道平滑肌、炎性细胞和免疫细胞的功能,选择性 PDE4b 抑制剂作为抗炎药治疗哮喘和慢性阻塞性肺病( COPD) 因为不会引起恶心呕吐等副反应而受到极大的关注。本文使用比较分子场( CoMFA) 方法,对系列嘧啶二芳基取代的 PDE4b 抑制剂构建了合理的三维定量构效关系( 3D-QSAR) 模型,使用分子对接方法研究了抑制剂与酶的相互作用,发现该系列化合物的嘧啶环 2 位引入带有较大电负性基团取代的五元环状烃基可提升活性;嘧啶环 4 位、5 位两个碳原子上建议保留小体积取代基;嘧啶环 6 位引入带有氢键给体或氢键受体取代的芳烃基可增加化合物活性。本研究可为后续合理设计高效的 PDE4b 抑制剂提供理论指导。     

N-(4'-取代嘧啶-2'-基)-2-甲氧羰基-5-(取代)苯甲酰胺基苯磺酰脲化合物的合成及除草活性研究

为进一步寻找高效、安全和对环境更加友好的除草剂,以商品化除草剂单嘧磺酯为研究基础,对其结构中的苯环5-位取代基作了结构修饰,合成了26个未见文献报道的新型N-(4'-取代嘧啶-2-基)-2-甲氧羰基-5-苯甲酰胺基苯磺酰脲化合物,通过1H NMR、质谱及元素分析确定了化合物的结构.经油菜平皿法及盆栽法测试了所有化合物的除草活性,结果表明,当苯环5-位取代基为苯甲酰胺时,活性较好,其对双子叶植物的除草活性与商品化的甲嘧磺隆相当.     

4-吡唑基-2-芳氧基嘧啶类化合物的合成及除草活性

以2,4-二氯嘧啶为起始原料, 利用两个氯原子的活性差异, 经4-吡唑基-2-氯嘧啶合成了一系列4-吡唑基-2-芳氧基嘧啶类化合物, 通过¹H NMR和元素分析对所合成的化合物进行了结构表征. 初步生物活性测定结果表明, 所合成的化合物都表现出一定的除草活性. 当嘧啶环2位的氯原子被芳氧基取代后, 化合物的除草活性均有不同程度的提高, 例如5c和4a相比, 100 μg•mL^－1时化合物对油菜的抑制率由15.7%提高到85.4%, 对稗草的抑制率由原来的11.6%提高到84.0%.     

新型含亲水基的噻唑烷-4-酮衍生物的合成及HIV逆转录酶抑制活性

在微波辐射条件下合成了系列C-2或N-3位含酯基的噻唑烷-4-酮衍生物,经水解或还原得到含亲水基如羧基、羟基的衍生物.化合物通过艾滋病毒逆转酶(HIV-RT)试剂盒(比色法)评价了其酶抑制活性.活性结果表明,部分化合物如8a,8b,9a,9b和14c能有效地抑制HIV逆转酶的活性.其中在N-3嘧啶环5位连有乙基的化合物8a和9a的活性最高,IC50值分别为3.02和3.06μmol·L-1.构效关系表明亲水性基团的引入对HIV逆转录酶抑制活性影响不大,而N-3位嘧啶基更有利于噻唑烷-4-酮抗HIV活性.     

N-(4'-取代嘧啶-2'-基)-2-甲氧羰基-5-(取代)苯甲酰胺基苯磺酰脲化合物的合成及除草活性研究

为进一步寻找高效、安全和对环境更加友好的除草剂, 以商品化除草剂单嘧磺酯为研究基础, 对其结构中的苯环5-位取代基作了结构修饰, 合成了26个未见文献报道的新型N-(4'-取代嘧啶-2'-基)-2-甲氧羰基-5-苯甲酰胺基苯磺酰脲化合物, 通过¹H NMR、质谱及元素分析确定了化合物的结构. 经油菜平皿法及盆栽法测试了所有化合物的除草活性, 结果表明, 当苯环5-位取代基为苯甲酰胺时, 活性较好, 其对双子叶植物的除草活性与商品化的甲嘧磺隆相当.     

磺酰脲类化合物除草活性的QSAR研究

采用密度泛函理论方法, 在B3LYP/6-31G(d)水平下, 计算了23种磺酰类化合物的分子极化率及分子骨架中各原子的Milliken电荷. 提出了一种新的QSAR建模方法, 并据此对其中18种化合物进行多元线性回归分析, 建立了除草活性的预测模型(R=0.96, R2=0.92, r2adj=0.88, F=26.26, q2=0.71, p<0.01, SE=0.36), 对剩余五种化合物进行预测, 结果吻合. 该模型从化合物的亲水性、分子几何特征的角度对如何提高磺酰脲类化合物的除草活性进行了分析, 并对提高化合物除草活性的方法做出预测: 提高苯环和嘧啶环取代基的亲水性, 增加N13周围的电子云密度, 为苯环接入较小的取代基团, 在嘧啶环上接入较大取代基团都可提高化合物的除草活性. 预测结果与3D-QSAR方法的预测结果一致.     

Importance of receptor flexibility in binding of cyclam compounds to the chemokine receptor CXCR4

We have elucidated the binding sites of four moncyclam and one bicyclam antagonist AMD3100, in the human chemokine receptor CXCR4. Using the predicted structural models of CXCR4, we have further predicted the binding sites of these cyclam compounds. We used the computational method LITiCon to map the differences in receptor structure stabilized by the mono and bicyclam compounds. Accounting for the receptor flexibility lead to a single binding mode for the cyclam compounds, that has not been possible previously using a single receptor structural model and fixed receptor docking algorithms. There are several notable differences in the receptor conformations stabilized by monocyclam antagonist compared to a bicylam antagonist. The loading of the Cu(2+) ions in the cyclam compounds, shrinks the size of the cyclam rings and the residue D262(6.58) plays an important role in bonding to the copper ion in the monocylam compounds while residue E288(7.39) is important for the bicyclam compound.     

Synthesis and bioactivity of a novel series of 3, 6-disubstituted 1, 2, 4-triazolo [3, 4-b]-1, 3, 4-thiadiazoles

<正>A novel series of 3,6-disubstituted 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles were synthesized by the condensation of 4-amino-5- [2-(4-chlorophenoxymethylbenzimidazole)-1-methylene]-3-mercapto-1,2,4-triazole with various(un)substituted aromatic acids in the presence of phosphorous oxychloride.These compounds were investigated for their inhibitory activity to E.coli methionine aminopeptidase(EcMetAP1).Some of the tested compounds showed significant inhibitory activity.     

Application of affinity selection-mass spectrometry assays to purification and affinity-based screening of the chemokine receptor CXCR4

Affinity selection-mass spectrometry (AS-MS) is a sensitive technology for identifying small molecules that bind to target proteins, and assays enabled by AS-MS can be used to delineate relative binding affinities of ligands for proteins. 'Indirect' AS-MS assays employ size-exclusion techniques to separate target-ligand complexes from unbound ligands, and target-associated ligands are then specifically detected by liquid chromatography mass spectrometry. We report how indirect AS-MS binding assays with known reference control compounds were used as guideposts for development of an optimized purification method for CXCR4, a G-protein coupled chemokine receptor, for which we sought novel antagonists. The CXCR4 purification method that was developed was amenable to scale-up and enabled the screening of purified recombinant human CXCR4 against a large combinatorial library of small molecules by high throughput indirect AS-MS. The screen resulted in the discovery of new ligands that competed off binding of reference compounds to CXCR4 in AS-MS binding assays and that antagonized SDF1α-triggered responses and CXCR4-mediated HIV1 viral uptake in cell-based assays. This report provides a methodological paradigm whereby indirect AS-MS-based ligand binding assays may be used to guide optimal integral membrane protein purification methods that enable downstream affinity selection-based applications such as high throughput AS-MS screens.     

Penicillixanthone A,a marine-derived dual-coreceptor antagonist as anti-HIV-1 agent

Marine micro-organisms have been proven to be excellent sources of bioactive compounds against HIV-1. Several natural products obtained from marine-derived Aspergillus fungi were screened for their activities to inhibit HIV-1 infection. Penicillixanthone A (PXA), a natural xanthone dimer from jellyfish-derived fungus Aspergillus fumigates, displayed potent anti-HIV-1 activity by inhibiting infection against CCR5-tropic HIV-1 SF162 and CXCR4-tropic HIV-1 NL4-3, with IC₅₀ of 0.36 and 0.26 μM, respectively. Molecular docking study was conducted to understand the possible binding mode of PXA with the CCR5/CXCR4. The results revealed that, the marine-derived PXA, as a CCR5/CXCR4 dual-coreceptor antagonist, presents a new type of potential lead product for the development of anti-HIV therapeutics.     

Ligand-guided optimization of CXCR4 homology models for virtual screening using a multiple chemotype approach

CXCR4 is a G-protein coupled receptor for CXCL12 that plays an important role in human immunodeficiency virus infection, cancer growth and metastasization, immune cell trafficking and WHIM syndrome. In the absence of an X-ray crystal structure, theoretical modeling of the CXCR4 receptor remains an important tool for structure–function analysis and to guide the discovery of new antagonists with potential clinical use. In this study, the combination of experimental data and molecular modeling approaches allowed the development of optimized ligand-receptor models useful for elucidation of the molecular determinants of small molecule binding and functional antagonism. The ligand-guided homology modeling approach used in this study explicitly re-shaped the CXCR4 binding pocket in order to improve discrimination between known CXCR4 antagonists and random decoys. Refinement based on multiple test-sets with small compounds from single chemotypes provided the best early enrichment performance. These results provide an important tool for structure-based drug design and virtual ligand screening of new CXCR4 antagonists.     

In vitro migration capacity of human adipose tissue-derived mesenchymal stem cells reflects their expression of receptors for chemokines and growth factors

The homing properties of adipose tissue-derived mesenchymal stem cells (AdMSCs) have stimulated intravenous applications for their use in stem cell therapy. However, the soluble factors and corresponding cellular receptors responsible for inducing chemotaxis of AdMSCs have not yet been reported. In the present study, the migration capacity of human AdMSCs (hAdMSCs) toward various cytokines or growth factors (GFs) and the expression of their receptors were determined. In a conventional migration assay, PDGF-AB, TGF-β1, and TNF-α showed the most effective chemoattractant activity. When AdMSCs were preincubated with various chemokines or GF, and then allowed to migrate toward medium containing 10% FBS, those preincubated with TNF-α showed the highest migratory activity. Next, hAdMSCs were either preincubated or not with TNF-α, and allowed to migrate in response to various GFs or chemokines. Prestimulation with TNF-α increased the migration activity of hAdMSCs compared to unstimulated hAdMSCs. When analyzed by FACS and RT-PCR methods, hAdMSCs were found to express C-C chemokine receptor type 1 (CCR1), CCR7, C-X-C chemokine receptor type 4 (CXCR4), CXCR5, CXCR6, EGF receptor, fibroblast growth factor receptor 1, TGF-β receptor 2, TNF receptor superfamily member 1A, PDGF receptor A and PDGF receptor B at both the protein and the mRNA levels. These results indicate that the migration capacity of hAdMSCs is controlled by various GFs and chemokines. Prior in vitro modulation of the homing capacity of hAdMSCs could stimulate their movement into injured sites in vivo when administered intravenously, thereby improving their therapeutic potential.     

99mTc-AMD3100: A novel potential receptor-targeting radiopharmaceutical for tumor imaging

<正>The chemokine CXCR4 receptor is over-expressed in a wide variety of tumors.In this study,AMD3100,which was a prototype non-peptide antagonist of CXCR4 receptor,was labeled with ~(99m)Tc.~(99m)Tc-AMD3100 was verified by thin layer radio chromatography(TLRC).The tumor-localizing properties of ~(99m)Tc-AMD3100 were evaluated and proved in mice bearing Hep-G2 tumor xenograft.~(99m)Tc-AMD3100 was a promising,novel receptor-specific radiopharmaceutical with potential application in the imaging of human tumors.     

Development of a linear type of low molecular weight CXCR4 antagonists based on T140 analogs

A linear type of several low molecular weight CXCR4 antagonists were developed based on T140 analogs, which were previously found to be strong CXCR4 antagonists that block X4-HIV-1 entry and have inhibitory activities against cancer metastasis/progression and rheumatoid arthritis.